| |
First bDMARD
|
DMARD use after baseline, as noted every 6 months on Corrona case report forms
|
|---|
|
0 months
|
6 months
|
12 months
|
18 months
|
24 months
|
30 months
|
36 months
|
42 months
|
48 months
|
54 months
|
60 months
|
|---|
|
(n = 7300)
|
(n = 7250)
|
(n = 6435)
|
(n = 5769)
|
(n =5153)
|
(n = 4658)
|
(n = 4175)
|
(n = 3723)
|
(n = 3359)
|
(n = 3054)
|
(n = 2764)
|
|---|
|
TCZ monotherapy
|
66 (0.90)
|
78 (1.08)
|
45 (0.70)
|
37 (0.64)
|
21 (0.41)
|
25 (0.54)
|
23 (0.55)
|
18 (0.48)
|
12 (0.36)
|
17 (0.56)
|
8 (0.29)
|
|
TCZ combination
|
117 (1.60)
|
128 (1.77)
|
117 (1.82)
|
122 (2.11)
|
123 (2.39)
|
109 (2.34)
|
97 (2.32)
|
67 (1.80)
|
59 (1.76)
|
47 (1.54)
|
45 (1.63)
|
|
TNFi, any
|
5889 (80.67)
|
4725 (65.17)
|
4000 (62.16)
|
3423 (59.33)
|
2980 (57.83)
|
2639 (56.66)
|
2284 (54.71)
|
1989 (53.42)
|
1764 (52.52)
|
1576 (51.6)
|
1402 (50.72)
|
|
nonTNF nonTCZ bDMARD
|
1228 (16.82)
|
1137 (15.68)
|
1027 (15.96)
|
938 (16.26)
|
852 (16.53)
|
802 (17.22)
|
749 (17.94)
|
707 (18.99)
|
671 (19.98)
|
609 (19.94)
|
575 (20.8)
|
|
csDMARD combination
|
–
|
946 (13.05)
|
996 (15.48)
|
998 (17.3)
|
946 (18.36)
|
880 (18.89)
|
812 (19.45)
|
761 (20.44)
|
690 (20.54)
|
657 (21.51)
|
597 (21.6)
|
|
No DMARD
|
–
|
236 (3.26)
|
250 (3.89)
|
251 (4.35)
|
231 (4.48)
|
203 (4.36)
|
210 (5.03)
|
181 (4.86)
|
163 (4.85)
|
148 (4.85)
|
137 (4.96)
|
- TCZ tocilizumab; TNFi TNF inhibitors; nonTNF nonTCZ bDMARD, includes all JAK inhibitors, abatacept, and rituximab; DMARD disease-modifying anti-rheumatic drugs; bDMARDs biologic DMARDs; csDMARDs conventional synthetic DMARDs
